

21 - References

References

Pharmacokinetics CHAPTER 11 References

1. Baldacci A, et al. Pharmacogenetic guidelines for psychotropic drugs: optimizing prescriptions in clinical practice. *Pharmaceutics* 2023; 15:2540.
2. Cojocar A, et al. The implications of cytochrome P450 2D6/CYP2D6 polymorphism in the therapeutic response of atypical antipsychotics in adolescents with psychosis – a prospective study. *Biomedicines* 2024; 12:494.
3. Daniel WA, et al. The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions. *Biochem Pharmacol* 2022; 199:115006.
4. Wójcikowski J, et al. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions. *Pharmacol Rep* 2020; 72:612–621.
5. Matura JM, et al. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations. *Ir J Med Sci* 2022; 191:2357–2365.
6. Danek PJ, et al. Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4. *Pharmacol Rep* 2021; 73:303–308.
7. Hart XM, et al. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics. *World J Biol Psychiatry* 2024:1–123.
8. Schoretsanitis G, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. *World J Biol Psychiatry* 2018; 19:162–174.
9. Indiana University School of Medicine. Drug Interactions Flockhart Table™ 2024 (last accessed August 2024); <https://drug-interactions.medicine.iu.edu/MainTable.aspx>.
10. Masimirembwa CM, et al. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. *Brain Res Bull* 1997; 44:561–571.
11. Aklillu E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. *Mol Pharmacol* 2003; 64:659.
12. Muscat JE, et al. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers. *Biochem Pharmacol* 2008; 76:929–937.
13. Wrighton SA, et al. The human hepatic cytochromes P450 involved in drug metabolism. *Crit Rev Toxicol* 1992; 22:1–21.

14. Rasmussen BB, et al. The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. *Pharmacogenetics* 2002; 12:473–478.
 15. Ingelman-Sundberg M, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoeconomic and clinical aspects. *Pharmacol Ther* 2007; 116:496–526.
 16. Stanford University. PharmGKB. 2024 (last accessed August 2024); <https://www.pharmgkb.org>.
 17. Zhou SF, et al. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. *AAPS J* 2009; 11:481–494.
 18. Myriad Genetics. Genesight. 2024 (last accessed August 2024); <https://www.genesight.com>.
 19. Enoch MA, et al. Using ancestry-informative markers to define populations and detect population stratification. *J Psychopharmacol* 2006; 20:19–26.
 20. Genetic Lifehacks. 2024 (last accessed August 2024); <https://www.geneticlifehacks.com>.
 21. Guttman Y, et al. Polymorphism in cytochrome P450 3A4 is ethnicity related. *Front Genet* 2019; 10:224.
 22. Darney K, et al. Inter-ethnic differences in CYP3A4 metabolism: a Bayesian meta-analysis for the refinement of uncertainty factors in chemical risk assessment. *Computational Toxicol* 2019; 12:100092.
-

Revision #1

Created 2026-01-04 20:18:11 UTC by Omar Ayman

Updated 2026-01-04 20:18:12 UTC by Omar Ayman